Episurf Medical AB (LTS:0QUT) Stock Based Compensation: kr0.40 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Episurf Medical AB Stock Based Compensation?

Episurf Medical AB LTS:0QUT -2.42% Stock Based Compensation is kr0.40 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Episurf Medical AB's Stock Based Compensation for the three months ended in Mar. 2026 was kr0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.40 Mil.

Episurf Medical AB Stock Based Compensation Related Terms

Episurf Medical AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Episurf Medical AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Episurf Medical AB Stock Based Compensation Chart

Episurf Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.30 -0.20 0.70 1.00 0.30

Episurf Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.10 0.20 0.10 0.00

Episurf Medical AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.40 Mil.

What does a Stock Based Compensation of kr0.40 Mil mean?
Episurf Medical AB (LTS:0QUT) has a Stock Based Compensation of kr0.40 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Episurf Medical AB and its competitors.
Is Episurf Medical AB's Stock Based Compensation too high?
Episurf Medical AB's current Stock Based Compensation is kr0.40 Mil.
How does Episurf Medical AB's Stock Based Compensation compare to ABT and SYK?
Episurf Medical AB's Stock Based Compensation of kr0.40 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Episurf Medical AB and its competitors. Episurf Medical AB's current Stock Based Compensation is kr0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Episurf Medical AB (LTS:0QUT) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.06 — trading 13% above its estimated fair value. The current Stock Based Compensation is kr0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Episurf Medical AB (LTS:0QUT), the current Stock Based Compensation is kr0.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Episurf Medical AB Business Description

Other Exchanges EPIS B:Sweden16E:Germany
Address Karlavagen 60, Stockholm, SWE, 114 49
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.